×
About 10,040 results

ALLMedicine™ Alopecia Center

Research & Reviews  3,047 results

Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Eve...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752075
Drug Design, Development and Therapy; Chanprapaph K, Pomsoong C et. al.

Jan 15th, 2022 - Intramuscular corticosteroids (IMC) have gained popularity for the treatment of severe alopecia areata (AA) in recent years; however, evidence on their efficacy and safety is still limited. To evaluate the efficacy, relapse rate, and tolerability ...

Epidemiologic features and risk of scarring in pediatric patients with kerion celsi.
https://doi.org/10.1111/pde.14916
Pediatric Dermatology; Friedland R, Sabbah F et. al.

Jan 15th, 2022 - Kerion celsi represents the inflammatory extreme of tinea capitis, as a delayed hypersensitivity reaction to the causative dermatophyte. Data regarding prevalence, trends in pathogens, and risk factors for scarring are limited. The main objective ...

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
https://clinicaltrials.gov/ct2/show/NCT05135468

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Preparation and optimization of aloe ferox gel loaded with Finasteride-Oregano oil nano...
https://doi.org/10.1080/10717544.2022.2026534
Drug Delivery; Hosny KM, Rizg WY et. al.

Jan 13th, 2022 - Alopecia areata is a skin disorder characterized by scarless, localized hair loss that is usually managed by topical treatments that might further worsen the condition. Therefore, the current study aimed to develop nano-cubosomes loaded with finas...

Performance of the systemic lupus erythematosus risk probability index in a cohort of u...
https://doi.org/10.1093/rheumatology/keac005
Rheumatology (Oxford, England); Erden A, Apaydın H et. al.

Jan 12th, 2022 - We sought to evaluate the performance of the systemic lupus erythematosus (SLE) Risk Probability Index (SLERPI) for identification of SLE in a large cohort of patients with undifferentiated connective tissue disease (UCTD). The SLERPI was applied ...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  266 results see all →

Clinicaltrials.gov  130 results

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
https://clinicaltrials.gov/ct2/show/NCT05135468

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
https://clinicaltrials.gov/ct2/show/NCT04764331

Jan 4th, 2022 - The purpose of this pilot study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for CCCA by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determin...

Long-Term PF-06651600 for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04006457

Dec 15th, 2021 - This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B793100...

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05129254

Dec 7th, 2021 - This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgen...

Fraxel Laser for Alopecia
https://clinicaltrials.gov/ct2/show/NCT03284021

Dec 6th, 2021 - This is a pilot study to evaluate the effect of the 1550 nm fractional erbium-glass laser in patients with nonscarring alopecias. Participants currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be consider...

see more →

News  563 results

Telemedicine Alopecia Assessment: Highlighting Patients With Skin of Color
https://www.mdedge.com/dermatology/article/250503/diversity-medicine/telemedicine-alopecia-assessment-highlighting-patients
Britney N. Wilson, MBS, Amy McMichael, MD et. al.

Jan 6th, 2022 - Practice Gap In accordance with World Health Organization guidelines on social distancing to limit transmission of SARS-CoV-2, dermatologists have relied on teledermatology (TD) to develop novel adaptations of traditional workflows, optimize patie.

Ripretinib Approval Advances Recurrent GIST Paradigm
https://www.onclive.com/view/ripretinib-approval-advances-recurrent-gist-paradigm

Jan 3rd, 2022 - Ripretinib (Qinlock) has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive dise...

Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond
https://www.onclive.com/view/nectin-4-emerges-as-a-therapeutic-target-in-urothelial-carcinoma-and-beyond

Jan 3rd, 2022 - In July 2021, the FDA granted full regulatory approval to enfortumab vedotin-ejfv (Padcev) for the treatment of patients with relapsed or refractory advanced/metastatic urothelial carcinoma.1 Previously awarded accelerated approval for this indica...

Oral JAK Inhibitor Continues to Show Promise for Alopecia Areata
https://www.medscape.com/viewarticle/965750

Dec 30th, 2021 - NEW YORK (Reuters Health) - Treatment with the investigational oral Janus kinase (JAK) inhibitors ritlecitinib or brepocitinib led to molecular and clinical improvement in scalp lesions in patients with alopecia areata enrolled in a biopsy sub-stu...

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma
https://www.onclive.com/view/ripretinib-demonstrates-impressive-efficacy-durability-in-heavily-pretreated-kit-mutated-melanoma

Dec 4th, 2021 - The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable...

see more →

Patient Education  7 results see all →